AI assistant
Relay Therapeutics, Inc. — Director's Dealing 2021
Dec 28, 2021
32320_dirs_2021-12-27_be8be287-81b2-439a-b07b-71daad205908.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Relay Therapeutics, Inc. (RLAY)
CIK: 0001812364
Period of Report: 2021-12-17
Reporting Person: Porter Andy (See Remarks)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 23407 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $5.042 | 2029-10-09 | Common Stock (143926) | Direct | |
| Stock Option (Right to Buy) | $5.22 | 2030-03-01 | Common Stock (13861) | Direct | |
| Stock Option (Right to Buy) | $5.22 | 2030-03-01 | Common Stock (47522) | Direct | |
| Stock Option (Right to Buy) | $34.25 | 2031-03-25 | Common Stock (28000) | Direct |
Footnotes
F1: Includes 12,250 restricted stock units ("RSUs") granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting. The RSUs commenced vesting in 16 equal quarterly installments following the grant date of March 26, 2021, subject to the reporting person's continued service with the Issuer through each vesting date.
F2: 24,239 shares underlying this option have vested and the remainder shall vest in equal quarterly installments from January 21, 2022 to October 21, 2023, subject to the reporting person's continued service with the Issuer through each vesting date.
F3: 2,970 shares underlying this option have vested and the remainder shall vest in equal quarterly installments from December 23, 2021 to June 23, 2024, subject to the reporting person's continued service with the Issuer through each vesting date.
F4: 11,880 shares underlying this option have vested and the remainder shall vest in equal quarterly installments from March 11, 2022 to December 11, 2024, subject to the reporting person's continued service with the Issuer through each vesting date.
F5: 3,500 shares underlying this option have vested and the remainder shall vest in equal quarterly installments from December 26, 2021 to March 26, 2025, subject to the reporting person's continued service with the Issuer through each vesting date.